These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Prolyl oligopeptidase inhibition attenuates the toxicity of a proteasomal inhibitor, lactacystin, in the alpha-synuclein overexpressing cell culture. Myöhänen TT; Norrbacka S; Savolainen MH Neurosci Lett; 2017 Jan; 636():83-89. PubMed ID: 27818354 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of prolyl oligopeptidase increases the survival of alpha-synuclein overexpressing cells after rotenone exposure by reducing alpha-synuclein oligomers. Dokleja L; Hannula MJ; Myöhänen TT Neurosci Lett; 2014 Nov; 583():37-42. PubMed ID: 25240592 [TBL] [Abstract][Full Text] [Related]
7. A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease. Myöhänen TT; Hannula MJ; Van Elzen R; Gerard M; Van Der Veken P; García-Horsman JA; Baekelandt V; Männistö PT; Lambeir AM Br J Pharmacol; 2012 Jun; 166(3):1097-113. PubMed ID: 22233220 [TBL] [Abstract][Full Text] [Related]
8. Prolyl oligopeptidase inhibition reduces alpha-synuclein aggregation in a cellular model of multiple system atrophy. Cui H; Kilpeläinen T; Zouzoula L; Auno S; Trontti K; Kurvonen S; Norrbacka S; Hovatta I; Jensen PH; Myöhänen TT J Cell Mol Med; 2021 Oct; 25(20):9634-9646. PubMed ID: 34486218 [TBL] [Abstract][Full Text] [Related]
10. Removal of proteinase K resistant αSyn species does not correlate with cell survival in a virus vector-based Parkinson's disease mouse model. Eteläinen TS; Kilpeläinen TP; Ignatius A; Auno S; De Lorenzo F; Uhari-Väänänen JK; Julku UH; Myöhänen TT Neuropharmacology; 2022 Nov; 218():109213. PubMed ID: 35964686 [TBL] [Abstract][Full Text] [Related]
11. New tricks of prolyl oligopeptidase inhibitors - A common drug therapy for several neurodegenerative diseases. Svarcbahs R; Julku U; Kilpeläinen T; Kyyrö M; Jäntti M; Myöhänen TT Biochem Pharmacol; 2019 Mar; 161():113-120. PubMed ID: 30660495 [TBL] [Abstract][Full Text] [Related]
12. The proSAAS Chaperone Provides Neuroprotection and Attenuates Transsynaptic α-Synuclein Spread in Rodent Models of Parkinson's Disease. Lindberg I; Shu Z; Lam H; Helwig M; Yucer N; Laperle A; Svendsen CN; Di Monte DA; Maidment NT J Parkinsons Dis; 2022; 12(5):1463-1478. PubMed ID: 35527562 [TBL] [Abstract][Full Text] [Related]
13. Prolyl Oligopeptidase Regulates Dopamine Transporter Oligomerization and Phosphorylation in a PKC- and ERK-Independent Manner. Julku UH; Jäntti M; Svarcbahs R; Myöhänen TT Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33579026 [TBL] [Abstract][Full Text] [Related]
14. Prolyl oligopeptidase inhibition by KYP-2407 increases alpha-synuclein fibril degradation in neuron-like cells. Rostami J; Jäntti M; Cui H; Rinne MK; Kukkonen JP; Falk A; Erlandsson A; Myöhänen T Biomed Pharmacother; 2020 Nov; 131():110788. PubMed ID: 33152946 [TBL] [Abstract][Full Text] [Related]
15. Inhibition-mediated changes in prolyl oligopeptidase dynamics possibly related to α-synuclein aggregation. Walczewska-Szewc K; Rydzewski J; Lewkowicz A Phys Chem Chem Phys; 2022 Feb; 24(7):4366-4373. PubMed ID: 35112120 [TBL] [Abstract][Full Text] [Related]
17. The effect of prolyl oligopeptidase inhibitors on alpha-synuclein aggregation and autophagy cannot be predicted by their inhibitory efficacy. Kilpeläinen TP; Hellinen L; Vrijdag J; Yan X; Svarcbahs R; Vellonen KS; Lambeir AM; Huttunen H; Urtti A; Wallen EAA; Myöhänen TT Biomed Pharmacother; 2020 Aug; 128():110253. PubMed ID: 32447211 [TBL] [Abstract][Full Text] [Related]
18. Nonpeptidic Oxazole-Based Prolyl Oligopeptidase Ligands with Disease-Modifying Effects on α-Synuclein Mouse Models of Parkinson's Disease. Kilpeläinen TP; Pätsi HT; Svarcbahs R; Julku UH; Eteläinen TS; Cui H; Auno S; Sipari N; Norrbacka S; Leino TO; Jäntti M; Myöhänen TT; Wallén EAA J Med Chem; 2023 Jun; 66(11):7475-7496. PubMed ID: 37248563 [TBL] [Abstract][Full Text] [Related]
19. Combining fibril-induced alpha-synuclein aggregation and 6-hydroxydopamine in a mouse model of Parkinson's disease and the effect of cerebral dopamine neurotrophic factor on the induced neurodegeneration. Singh A; Panhelainen A; Reunanen S; Luk KC; Voutilainen MH Eur J Neurosci; 2024 Jan; 59(1):132-153. PubMed ID: 38072889 [TBL] [Abstract][Full Text] [Related]